Friday, March 18, 2016
West Campus Conference Center, Yale University

8:00 – 8:30 Coffee and registration

8:30 – 8:40 **Welcoming remarks** – Diane Krause (Yale University)

8:40 – 9:15 **Chimeric antigen receptor (CAR) T cell therapy for B cell cancers**
Renier Brentjens (Memorial Sloan Kettering Cancer Center)

9:15 – 9:50 **CAR T cells: what next after B cell malignancies?**
Marcela Maus (Massachusetts General Hospital, Harvard University)

9:50 – 10:10 Coffee break

10:10 – 10:45 **Bench-to-bedside and back. How T-cell gene therapy has benefited from a partnership between academia and industry.**
Laurence Cooper (MD Anderson Cancer Center/ ZioPharm Oncology)

10:45 – 11:20 **Preclinical Optimization of CD20 CAR T cell Adoptive Transfer.**
Brian Till (Fred Hutchinson Cancer Center)

11:20 – 12:20 **Panel Discussion: CAR T-cell therapies: New targets and perspectives**
Panelists: Renier Brentjens, Marcela Maus, Laurence Cooper, Brian Till

12:20 – 1:30 Lunch with sponsor presentation (BioLife Solutions):
**Cold chain logistics for cellular therapy products**

1:30 – 2:05 **Adoptive cell therapy, the Moffitt experience**
Amod Sarnaik (Moffit Cancer Center)

2:05 – 2:40 **Virus-specific T cells after transplant: Broadening applicability**
Catherine Bollard (Children’s National Medical Center)

2:40 – 3:00 Coffee break

3:00 – 3:35 **Hematopoietic Cell Transplant as a Model System for Understanding HIV**
Ann Woolfrey (Fred Hutchinson Cancer Center)

3:35 – 4:10 **Cell therapy of cancer in the era of checkpoint inhibitors**
Lieping Chen (Yale University)

4:10 – 5:05 **Panel Discussion: Challenges in translation of immunocellular therapies and technology transfer**
Panelists: Amod Sarnaik, Catherine Bollard, Laurence Cooper, Renier Brentjens

5:05 – 5:15 **Closing remarks** – Alexey Bersenev (Yale University)